Ce1 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.013
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pdb76 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Liraglutide Based on Cardiovascular Outcome Trials

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Pdb62 - Cost-Effectiveness Analysis of Empagliflozin in Japan Based on Results From the Subgroup Analysis of Asian Patients in the Empa-Reg Outcome Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pdb73 - Indirect Cost-Effectiveness Analysis of Empagliflozin Compared to Canagliflozin for Patients With T2dm and Cardiovascular Disease in the Spanish National Health Service

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pdb63 - Cost-Effectiveness Analysis of Empagliflozin Treatment in Patients With Type 2 Diabetes and Chronic Heart Failure Based on Subgroup of Empa-Reg Outcome in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients

Open Access Macedonian Journal of Medical Sciences
Medicine
2019English

Cost-Effectiveness of Saxagliptin and Linagliptin in Combination With Metformin for Type II Diabetes: A Decision-Tree Analysis Model

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results From the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study

Metabolism: Clinical and Experimental
EndocrinologyMetabolismDiabetes
2020English

Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials

Medical Decision Making
Health Policy
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy